- Joe Stringer, Dr Pooja Sikka and Shamik Parekh join from TenX Health
- Intends to raise £100m to invest in early-stage health tech, with Octopus Group as cornerstone investor
Octopus Ventures, part of Octopus Group and one of the largest and most active VCs in Europe, today announced it is boosting its health tech offering with a new team from TenX Health as it looks to launch a new £100 million institutional global fund to take advantage of the health tech market opportunity.
The team of three builds on Octopus’ existing expertise in the rapidly evolving health tech space, enabling the investor to accelerate its coverage of the sector, in particular the opportunity to transform public healthcare systems across Europe and the emerging markets.
Joe Stringer, Dr Pooja Sikka and Shamik Parekh join Octopus Ventures from TenX Health, and bring with them a wealth of experience and a deep and broad network in the digital healthcare space. Joe and Pooja were formerly founding members of EY Ventures, leading the health and social care portfolio.
The team will manage the proposed fund, which is targeting £100 million to invest in early-stage health tech businesses. The fund aims to accelerate healthcare technology into global health systems and directly to consumers that need better access to healthcare. It will focus on Series A, reserving capital to follow on throughout the growth rounds. Octopus Group will be the cornerstone investor, bringing its strong track record and experience to the table.
Commenting on the news, Alliott Cole, Co-CEO of Octopus Ventures, said:
“Covid-19 has doubled the pace of growth in healthcare technology. Joe, Pooja and Shamik’s arrival and the launch of the fund puts us in an even stronger position to take advantage of the investment opportunities that are emerging from the pandemic as the digital healthcare revolution continues. We now have one of the largest teams backing those entrepreneurs that are radically rethinking how healthcare can be delivered – across Europe as well as expanding our footprint into emerging markets. We are delighted to cornerstone this new fund and look forward to providing investors with an opportunity to access this global growth market.”
Joe Stringer said:
“Octopus is one of the most active technology investors in early-stage companies in Europe and already has a strong track record in backing pioneering entrepreneurs that are changing the way healthcare is delivered. This breadth of experience, combined with the group’s outstanding fund management platform, makes it an exciting partner for us to accelerate our plans to support the revolution we are seeing in digital health through the new fund. Coronavirus has put immense pressure on our healthcare systems and has been a catalyst for the mass adoption of tech to help improve patient care. This change is here to stay and with that comes an opportunity to develop meaningful health tech that can really make a difference to the lives of millions around the world.”
Dr Pooja Sikka added:
“Combined with the growth potential in technology and the positive social impact of the sector, digital health has swung sharply into the spotlight. There is a massive opportunity to back businesses that can really make a difference to the way healthcare is delivered to the benefit of patients across Europe and the emerging markets. We are looking forward to unlocking this potential with our new fund, building on Octopus’ reputation as one of Europe’s leading VCs and its mission to achieve impact at scale and pace.”
The news follows swiftly on the heels of Emma Davies joining Octopus Ventures as Co-CEO this month, bringing over 20 years of institutional fund management expertise, and Octopus’ announcement in October that it had scaled its portfolio team by 45% with nine new hires, as well as launching a new specialist consumer team.
The recent announcements signal Octopus Ventures’ intention to dial up its investment activity, particularly in high impact sectors, despite the market uncertainty caused by Covid-19, as it continues to create opportunities for investors to back pioneering entrepreneurs and access the growth potential these businesses offer.
Note to Editors:
This press release is issued by Octopus Investments Limited. Octopus Ventures is part of Octopus Investments, which is authorised and regulated by the Financial Conduct Authority. The information contained within this press release does not constitute an offer or inducement to participate in a collective investment scheme, alternative investment fund or any other financial product and may not be treated as an offer or inducement in any jurisdiction where such an offer or inducement is against the law, or to anyone to whom it is unlawful to make such an offer or solicitation, or if the person making the offer or solicitation is not qualified to do so. Our investments place investors’ capital at risk and they may not get back the full amount invested. This promotion does not offer investment or tax advice and this product is not suitable for everyone. We recommend investors seek independent investment and tax advice before investing in our products. Octopus Investments Limited is authorised and regulated by the Financial Conduct Authority. Registered office: 33 Holborn, London EC1N 2HT. Registered in England and Wales No. 3942880. We record our telephone calls. Issued: January 2021.